Similar Papers

Paper Title
Journal
Date
Author
Reference Pricing and Price Negotiations for Innovative New Drugs
Afschin Gandjour
PharmacoEconomics | VOL. 31
Afschin GandjourAfschin Gandjour
06 Nov 2012
Implementation of Value-based Pricing for Medicines
Claudio Jommi ... Monica Otto
Clinical Therapeutics | VOL. 42
Claudio Jommi, et. al.Claudio Jommi ... Monica Otto
24 Dec 2019
Market access and value-based pricing of digital health applications in Germany
Daniel Gensorowsky ... Wolfgang Greiner
Cost Effectiveness and Resource Allocation | VOL. 20
Daniel Gensorowsky, et. al.Daniel Gensorowsky ... Wolfgang Greiner
13 Jun 2022
A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing
Brian Godman ... Lars L Gustafsson
Applied Health Economics and Health Policy | VOL. 11
Brian Godman, et. al.Brian Godman ... Lars L Gustafsson
16 Jan 2013
View more papers

More From: Diabetes care

Paper Title
Journal
Date
Author
Sodium-Glucose Cotransporter 2 Inhibitors and Lower-Extremity Amputation: Is the Guilty Verdict Valid?
Meng Pan ... Til Stürmer
Diabetes care | VOL. -
Meng Pan, et. al.Meng Pan ... Til Stürmer
28 Jan 2025
Longitudinal Associations of PFAS Exposure With Insulin Sensitivity and β-Cell Function Among Hispanic Women With Gestational Diabetes Mellitus History.
Ni Kang ... Zhanghua Chen
Diabetes care | VOL. -
Ni Kang, et. al.Ni Kang ... Zhanghua Chen
28 Jan 2025
Diabetes Risk After Treatment for Childhood and Young Adult Cancer.
Kirsten J Cromie ... Adam W Glaser
Diabetes care | VOL. -
Kirsten J Cromie, et. al.Kirsten J Cromie ... Adam W Glaser
24 Jan 2025
Erratum. 7. Diabetes Technology: Standards of Care in Diabetes-2025. Diabetes Care 2025;48(Suppl. 1):S146-S166.
Diabetes care | VOL. -
23 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.